Neither PD-L1 positive nor negative is straightforwardly “better.” PD-L1 status is not a simple good-or-bad result. It tells your oncologist how your tumor interacts with your immune system, which shapes which treatments are most likely to work. A positive result means you’re more likely to respond to immunotherapy drugs on their own, but it also signals that the tumor has found a way to hide from your immune defenses. A negative result means immunotherapy alone is less effective, but combination treatments can still produce strong results.
What PD-L1 Actually Does
PD-L1 is a protein that sits on the surface of cells, including tumor cells. It works like an “off switch” for your immune system. When PD-L1 on a tumor cell connects with a receptor called PD-1 on a T cell (one of your body’s main cancer-fighting cells), it shuts the T cell down. The T cell stops attacking, stops producing the chemical signals it uses to coordinate an immune response, and can even self-destruct. This is how tumors with high PD-L1 expression hide in plain sight: they essentially tell your immune system to stand down.
In healthy tissue, this mechanism exists for a good reason. It prevents your immune system from becoming overactive and attacking your own body. But cancers hijack this system to protect themselves.
What Your PD-L1 Score Means
PD-L1 testing is most commonly done in non-small cell lung cancer (NSCLC), but it’s used in many other cancers too. The result is typically reported as a percentage using one of two scoring methods. The Tumor Proportion Score (TPS) measures only the percentage of tumor cells expressing PD-L1. The Combined Positive Score (CPS) counts both tumor cells and nearby immune cells, then expresses the result relative to total tumor cells.
For lung cancer, the key cutoffs are:
- Negative: TPS below 1%, meaning very few or no tumor cells display PD-L1
- Low positive: TPS 1% to 49%
- High positive: TPS 50% or greater
For other cancer types where CPS is the standard scoring method, the thresholds are slightly different, often using cutoffs of 1%, 10%, and 20%. Your oncologist interprets the number based on the specific cancer you have and the treatment options available.
PD-L1 Positive: Better Immunotherapy Response, but a More Aggressive Tumor
This is the core paradox of PD-L1 status. Being positive means immunotherapy drugs, called checkpoint inhibitors, are more likely to work for you. These drugs block the PD-L1/PD-1connection, removing the tumor’s disguise so your T cells can attack it again. In NSCLC patients with PD-L1 scores of 50% or higher, immunotherapy alone produces response rates around 45% to 58%, compared to about 27% with standard chemotherapy.
Long-term data from a global registry of advanced lung cancer patients with high PD-L1 (50% or above) treated with immunotherapy showed a 5-year survival rate of roughly 27%. That may sound modest, but for advanced lung cancer, where survival beyond five years was once rare, it represents a meaningful shift.
The flip side is that PD-L1 positivity, in the absence of treatment, tends to correlate with more aggressive disease. Across many cancer types, including gastric, esophageal, pancreatic, bladder, and lung cancers, higher PD-L1 expression is associated with larger tumors, deeper tissue invasion, more lymph node spread, and more advanced staging at diagnosis. In lung cancer specifically, PD-L1 positive patients who did not receive immunotherapy had shorter overall survival than PD-L1 negative patients. The tumor’s ability to silence the immune system lets it grow more freely.
So PD-L1 positivity is a double-edged finding: the tumor is actively suppressing your immune system, but that same vulnerability makes it a target for immunotherapy.
PD-L1 Negative: Fewer Options, but Not No Options
If your tumor is PD-L1 negative, immunotherapy drugs used alone are significantly less effective. In PD-L1 negative lung cancer, single-agent immunotherapy produces a response rate of only about 11%, with a median progression-free survival of just 2.3 months. That’s not a strong enough benefit to justify using immunotherapy on its own.
The good news is that combination approaches change the picture dramatically. Adding immunotherapy to platinum-based chemotherapy in PD-L1 negative patients pushes the response rate up to about 48%, with median progression-free survival reaching 6.8 months and overall survival around 15.6 months. That combination, particularly using a checkpoint inhibitor with standard chemotherapy, improved progression-free survival by 45% compared to chemotherapy alone. Another approach pairs two different types of immunotherapy together (one targeting PD-1 and another targeting a different checkpoint called CTLA-4), which showed the longest overall survival in this group at 17.6 months.
For PD-L1 negative patients, the chemotherapy component appears to play a crucial role. Chemotherapy kills some tumor cells outright, but it also releases signals that can “wake up” the immune system and make remaining tumor cells more visible to T cells. This creates an opening for the immunotherapy drug to work even when PD-L1 levels are low.
Why PD-L1 Status Doesn’t Tell the Whole Story
PD-L1 testing has real limitations. The score can vary depending on where in the tumor the biopsy was taken, because PD-L1 expression isn’t uniform across an entire tumor. It can also change over time, especially after treatment. Two different testing methods can sometimes give different results on the same tissue sample, though three of the four approved lab tests are considered largely interchangeable.
Some patients with negative PD-L1 still respond to immunotherapy, and some patients with high PD-L1 don’t respond at all. PD-L1 is the best biomarker currently available for predicting immunotherapy benefit, but it captures only one piece of a complex interaction between your tumor and your immune system. Other factors, like how many immune cells have infiltrated the tumor and the overall number of genetic mutations in the cancer cells, also influence how well treatment works.
What This Means for Your Treatment
If you’re PD-L1 high positive (50% or above in lung cancer), you may be offered immunotherapy as a standalone first-line treatment. If you’re low positive (1% to 49%), immunotherapy combined with chemotherapy is the more common approach. If you’re negative, combination therapy with chemotherapy plus immunotherapy remains effective and is now a standard strategy rather than a last resort.
The most important takeaway is that PD-L1 status guides treatment decisions rather than determining your fate. A positive result opens the door to immunotherapy as a primary weapon. A negative result narrows that door but doesn’t close it, and combination regimens can produce outcomes that rival what immunotherapy alone achieves in positive patients. The question isn’t whether one result is universally better. It’s which result you have, and what your oncologist can do with that information.